

## AMENDMENTS

### Listing of Claims

The following listing of claims replaces all previous listings or version thereof:

- 1-10. (Canceled)
11. (Currently amended) A method for identifying a compound that modulates an FKHL7 ~~bioactivity~~DNA-binding activity, comprising the steps of:
- (a) contacting the compound with a cell or cellular extract, which expresses an FKHL7 gene product having the amino acid sequence of SEQ ID NO:2; and
  - (b) determining the resulting FKHL7 ~~bioactivity~~DNA-binding activity,
- wherein an increase or decrease in the FKHL7 ~~bioactivity~~DNA-binding activity in the presence of the compound as compared to the ~~bioactivity~~DNA-binding activity in the absence of the compound indicates that the compound is a modulator of an FKHL7 ~~bioactivity~~DNA-binding activity.
12. (Previously presented) The method of claim 11, wherein the compound is an agonist of an FKHL7 ~~bioactivity~~DNA-binding activity.
13. (Previously presented) The method of claim 11, wherein the compound is an antagonist of an FKHL7 ~~bioactivity~~DNA-binding activity.
14. (Previously presented) A compound that has been identified according to the method of claim 11.
15. (Previously amended) The method of claim 11, wherein the compound is selected from the group consisting of a polypeptide, a nucleic acid, a peptidomimetic, and a small molecule.
16. (Previously amended) The method of claim 15, wherein the small molecule is a steroid.

17. (Previously amended) The method of claim 15, wherein the nucleic acid is a member selected from the group consisting of a gene replacement, an antisense, a ribozyme, and a triplex nucleic acid.
18. (Currently amended) A method for identifying a compound that modulates ~~an~~-FKHL7 ~~bioactivity~~DNA-binding activity comprising the steps of:
  - (a) combining an FKHL7 protein having the amino acid sequence of SEQ ID NO:2, and FKHL7 binding partner, and a test compound under conditions wherein, but for the test compound, the FKHL7 protein and FKHL7 binding partner are able to interact; and
  - (b) detecting the formation of an FKHL7 protein/FKH7 binding partner complex, such that a difference in the formation of an FKHL7 protein/FKHL7 binding partner complex in the presence of a test compound relative to in the absence of the test compound indicates that the test compound is a modulator of ~~an~~-FKHL7 DNA-binding activity.
19. (Currently amended) The method of claim 18, wherein the test compound is selected from the group comprising a polypeptide, a nucleic acid, a peptidomimetic, and a small molecule.
20. (Previously presented) The method of claim 19, wherein the small molecule is a steroid.
21. (Previously presented) The method of claim 19, wherein the nucleic acid is a member selected from the group consisting of a gene replacement, an antisense, a ribozyme, and a triplex nucleic acid.
22. (Currently amended) The method of claim 18, wherein the test compound is an agonist of on FKHL7 ~~bioactivity~~DNA-binding activity.
23. (Currently amended) The method of claim 18, wherein the test compound is an antagonist of on FKHL7 ~~bioactivity~~DNA-binding activity.

24. (Previously presented) A compound that has been identified according to the method of claim 18.